# US 2026/0216091 A1 · Nanoparticle compositions and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0216091 A1
- Document ID: US20260216091A1
- Status: Published application
- Kind: A1
- Application number: 19/280,907
- Filed: 2025-07-25
- Published: 2026-07-30
- Earliest claimed: 2020-05-14
- Assignees: Op-T LLC; The Regents of the University of Colorado, a body corporate
- Applicants: Op-T LLC; The Regents of the University of Colorado, a body corporate
- Inventors: David H. Wagner, JR.; Martin G. Yussman; Gisela M. Vaitaitis; Charles W. Henry
- Web page: https://patentgrep.com/patent/US20260216091A1

## CPC

- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/5031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)}
- A61K 9/5192: {Processes}
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/179: {for growth factors; for growth regulators}
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/6923: {the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb}
- A61K 47/6925: {the form being a microcapsule, nanocapsule, microbubble or nanobubble}
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61K 47/6937: {the polymer being PLGA, PLA or polyglycolic acid}
- C07K 14/70575: {NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525)}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present developments provide methods and compositions for treating and/or preventing autoimmune diseases. In certain aspects, the present disclosure relates to the use of short peptides loaded inside of nanoparticle nanospheres, nanocapsules, or PEGylated nanoparticles. Additionally, peptide-metal nanoparticle drug conjugates are described and disclosed. In some embodiments, these nanoparticles, whether polymer based or metal-conjugated, when linked or coupled to bioactive peptides provided herein, may be capable of interacting with CD40 proteins or CD40 complexes, and thereby may interfere with the ability of CD40 to interact with CD154. The present disclosure also relates to the use of such nanoparticle-peptide conjugates in reducing the inflammatory response, and in particular, the autoimmune inflammatory response. The present disclosure also relates to the use of such short peptides to prevent or reverse autoimmune disease, in particular in type 1 diabetes and multiple sclerosis, in individuals suffering from such diseases.

## Claims

### Claim at position 1

-117. (canceled)

### Claim 118

A method of treating alopecia in a subject comprising administering to the subject a therapeutically effective amount of a peptide comprising the amino acid sequence of SEQ ID NO: 7.

### Claim 119 (depends on 118)

The method of claim 118, wherein the alopecia is an autoimmune related or induced alopecia.

### Claim 120 (depends on 118)

The method of claim 118, wherein the peptide comprises a chemical modification.

### Claim 121 (depends on 120)

The method of claim 120, wherein the peptide is pegylated or glycosylated.

### Claim 122 (depends on 120)

The method of claim 120, wherein the peptide is modified by acetylation on the N-terminus and/or amidation on the C-terminus.

### Claim 123 (depends on 118)

The method of claim 118, wherein the peptide binds to a CD40 protein with a Kd of less than 10-6.

### Claim 124 (depends on 118)

The method of claim 118, wherein the peptide affects an interaction of CD40 with a CD40 ligand.

### Claim 125 (depends on 118)

The method of claim 118, wherein the peptide affects the interaction of CD40 and CD154.

### Claim 126 (depends on 118)

The method of claim 118, wherein the peptide inhibits the binding of CD40 to CD154.

### Claim 127 (depends on 118)

The method of claim 118, wherein the peptide prevents expansion of Th40 cells.

### Claim 128 (depends on 118)

The method of claim 118, wherein the peptide does not elicit antibody production in the subject.

### Claim 129 (depends on 118)

The method of claim 118, wherein the peptide reduces hair loss in the subject.

### Claim 130 (depends on 118)

The method of claim 118, wherein the peptide is 15 amino acid long.

### Claim 131 (depends on 118)

The method of claim 118, wherein the peptide consists of the amino acid sequence of SEQ ID NO: 7.
